Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply
Citation
Jones RH, Casbard A, Carucci M, Foxley A, Howell SJ. Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply. Lancet Oncol. 2020;21(5):e234.Journal
Lancet OncologyDOI
10.1016/s1470-2045(20)30237-0PubMed ID
32359499Additional Links
https://dx.doi.org/ 10.1016/s1470-2045(20)30237-0Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(20)30237-0
Scopus Count
Collections
Related articles
- Fulvestrant plus capivasertib for metastatic breast cancer.
- Authors: Ludmir EB, McCaw ZR, Kim DH, Tian L, Wei LJ
- Issue date: 2020 May
- Fulvestrant plus capivasertib for metastatic breast cancer.
- Authors: Dekker TJA
- Issue date: 2020 May
- Capivasertib inhibits a key pathway in metastatic breast cancer.
- Authors: Nasrazadani A, Brufsky AM
- Issue date: 2020 Mar
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
- Authors: Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM
- Issue date: 2020 Feb
- [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
- Authors: Sakurai K, Fujisaki S, Suzuki S, Adachi K, Nagashima S, Masuo Y, Tomita R, Gonda K, Enomoto K, Amano S, Matsuo S, Umeda N
- Issue date: 2015 Oct